Innate Pharma Income Statement (2018-2025) | IPHA

Income Statement Dec2018 Jun2019 Dec2019 Jun2020 Dec2020 Jun2021 Dec2021 Jun2022 Dec2022 Jun2023 Dec2023 Jun2024 Dec2024 Jun2025
Revenue & cost
Revenue 0.08B0.00B0.07B0.01B0.02B50.58B0.04B0.06B0.01B0.01B0.00B
Operating items
Research & Development -0.09B-0.03B-0.06B0.00B-0.05B-0.03B-0.00B-0.03B-0.06B-0.03B-0.06B-0.02B
Selling, General & Administrative -0.03B-0.02B-0.02B0.01B-0.03B-0.01B-0.00B-0.01B-0.02B-0.01B-0.02B-0.01B
Other Operating Expenses 0.00B0.00
Operating Expenses -0.12B-0.05B-0.08B0.01B-0.08B-0.04B-0.00B-0.04B-0.08B-0.04B-0.08B-0.03B
Operating Income -0.02B-0.01B0.01B-0.05B-0.06B-0.00B-0.01B-0.03B-0.05B-0.03B
EBIT -0.02B-0.01B0.01B-0.05B-0.06B-0.00B-0.01B-0.03B-0.05B-0.03B
Non-operating items
Non Operating Income -0.00B-0.00B-0.00B-557.06
Net income details
EBT -0.02B-0.00B0.01B-0.05B-0.06B0.00B-0.01B-0.03B-0.05B-0.03B
Profit After Tax -0.02B-10.33B-0.08B-0.03B-0.06B-0.06B0.00B-0.01B-0.03B-0.05B-0.02B
Net Income - Minority -0.19B-0.24B-0.24B-0.23B-0.19B-0.12B-0.06B-0.06B-0.01B
Income from Continuing Operations -0.02B-0.00B0.01B-0.05B-0.06B0.00B-0.01B-0.03B-0.05B-0.03B
Consolidated Net Income -0.02B-0.00B-0.08B0.01B-0.01B-0.00B-133.650.00B-0.01B-0.03B-0.05B-0.03B
Income towards Parent Company -0.19B-0.24B-0.26B-0.23B-0.26B0.01B-0.13B-0.00B-0.06B0.00B-0.06B-0.03B-0.06B-0.03B
Net Income towards Common Stockholders -0.19B-0.24B-0.26B-0.23B-0.26B0.01B-0.13B-0.00B-0.06B0.00B-0.06B-0.03B-0.06B-0.03B
Additional items
EPS (Basic) -0.00B-3.40-3.49-0.00B-2.780.00B-1.44-912.50-0.680.00B-0.72-0.00B-0.67-0.00B
EPS (Weighted Average and Diluted) -0.00B-0.00B0.08-912.500.00B-0.00B-0.00B
Shares Outstanding (Weighted Average) 57.070.07B0.07B143.190.09B361.280.09B85.360.08B21.780.09B333.840.09B282.99
Shares Outstanding (Diluted Average) 57.07143.190.10B85.3621.78333.84282.99
EBITDA -0.02B-0.01B0.01B-0.05B-0.06B-0.00B-0.01B-0.03B-0.05B-0.03B
Interest Expenses -0.01B-0.00B-0.01B-0.00B-0.01B-0.00B-0.00B-0.00B-0.00B-0.00B-0.00B